Vamsidhar Velcheti, MD, on NSCLC: Sotorasib in KRAS-Mutated Disease

June 07, 2021 By The ASCO Post Staff

Vamsidhar Velcheti, MD, of New York University, discusses overall survival and exploratory subgroup analyses from the phase II CodeBreaK 100 trial, which evaluated the use of sotorasib in pretreated KRAS G12C–mutant non–small cell lung cancer (Abstract 9003).

Related Content